Nintedanib Eg (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, PDGFR and FGFR. By inhibiting these signals, the drug reduces fibroblast proliferation, angiogenesis, and extracellular matrix formation, which together limit fibrotic tissue remodeling and tumor‑driven blood vessel formation.

The exact dose of Nintedanib Eg is determined by the prescribing clinician based on the patient’s specific condition, disease severity, renal and hepatic function, and any concomitant medications. Dosage adjustments are made according to clinical response and tolerability, not by a fixed schedule.

Safety data for Nintedanib in pregnancy and lactation are limited, and the drug is classified as contraindicated or not recommended for use in these situations. Women of child‑bearing potential should use effective contraception, and breastfeeding mothers should avoid the medication unless the benefits outweigh potential risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Nintedanib Eg. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The primary alternative antifibrotic is pirfenidone. Both agents aim to slow disease progression in idiopathic pulmonary fibrosis, but they differ in mechanism—pirfenidone modulates cytokine production, while Nintedanib inhibits multiple tyrosine kinases. Choice between them depends on patient tolerance, liver function, drug‑interaction profile, and physician judgment.

Nintedanib Eg should be stored at room temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, direct sunlight, and excessive heat. Do not refrigerate or freeze the product, and ensure the container remains tightly closed until use.

Nintedanib Eg is taken orally, usually with a full glass of water. It is recommended to swallow the tablet whole and not to crush or chew it. Dosing times (e.g., with food) are guided by the prescriber to improve tolerability and absorption.

The most serious adverse events include hepatotoxicity (elevated liver enzymes or liver injury), severe bleeding (especially when combined with anticoagulants), and cardiovascular complications such as myocardial infarction. Patients should be monitored regularly for liver function, signs of bleeding, and cardiac symptoms.

Nintedanib Eg is contraindicated in patients with severe hepatic impairment, those who are pregnant or breastfeeding, and individuals with uncontrolled bleeding disorders. Caution is also advised for patients with significant cardiovascular disease, and the drug should be avoided in anyone with known hypersensitivity to Nintedanib or its excipients.